Antiphospholipid antibodies and their clinical importance
Authors:
Z. Fojtík
Authors‘ workplace:
Interní hematoonkologická klinika, FN Brno
Published in:
Čes. Revmatol., , 2004, No. 3, p. 103-109.
Category:
Overview
Antiphospholipid antibodies (APLA) represent a heterogenous group of antibodieswhichmayaffectdifferent coagulation cascade pathways by analogy with involvement of phospholipid surfaces invarious steps of blood coagulation. The result of this process leads usually to some degree ofthrombophilia. The most frequently detected APLA are represented by lupus anticoagulant (LA)and anticardiolipin antibodies (aCL). Protein cofactors of antigen determinantswhich are involvedinAPLAgeneration are β2-GPI, prothrombin, proteinC, protein S, annexinV, high andlow molecularmass kininogen, factor XII, thrombomodulin and tissue plasminogen activator. A majority of thesefactors participate in the initial phase of coagulation cascade or in additional mechanisms ofchecking on the cascade. It is possible that antibodies against these proteins can affect coagulationbalance. The syndrome represented by positive LA and aCL antibodies has been called antiphospholipidsyndrome. The basic concept of this syndrome is characterized by thrombophilic syndrome.The main spectrum of clinical manifestations of APS includes arterial and venous thromboses,spontaneous fetal losses and thrombocytopenia.
Key words:
lupus anticoagulant, antiphospholipid syndrome
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2004 Issue 3
Most read in this issue
- Antiphospholipid antibodies and their clinical importance
- Diurnal variation of prolactin secretion inrheumatoid arthritis patients
- Upper dysphagia in patient with diffuse idiopathic skeletal hyperostosis
- Simultaneous affection of central and peripheral nervous system in systemic lupus erythematosus patients